J&J (JNJ +0.85%) Q4 net profit $3.52B vs $2.57B a year earlier.
Domestic sales +7.4%, international sales +2.4%
2013 results were "led by the outstanding performance in our pharmaceutical business, the strength of key brands in our U.S. OTC and other consumer businesses, and continued progress in integrating Synthes into our Medical Devices and Diagnostics business," says J&J CEO Alex Gorsky.
J&J expects 2014 EPS of $5.75-5.85 vs consensus of $5.85. (PR)